Exchange: NasdaqGS Sector: Healthcare Industry: Biotechnology
-4.46% $0.540
Last updated: 16 May 2022 @ 10:14 am
FUNDAMENTALS | |
---|---|
MarketCap: | 23.45 mill |
EPS: | -1.319 |
P/E: | 0.000 |
Earnings Date: | Feb 24, 2022 |
SharesOutstanding: | 43.45 mill |
Avg Daily Volume: | 0.119 mill |
RATING 2022-05-13 |
---|
B |
Neutral |
RATINGDETAILS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
Revenue | ||||||
Gr.Profit | n/a | n/a | n/a | |||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a |
True Range Average |
---|
+/- $0.0990 ( +/- 17.52%) Range: 0.466 - 0.664 |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-01-20 | Busch Andreas | Buy | 135 000 | Employee Stock Option (Right to Buy) |
2022-01-20 | Gjino Anjeza | Buy | 135 000 | Employee Stock Option (Right to Buy) |
2022-01-20 | Hecht Peter M | Buy | 430 000 | Employee Stock Option (Right to Buy) |
2022-01-20 | Hecht Peter M | Buy | 52 950 | Employee Stock Option (Right to Buy) |
2022-01-20 | Gault Cheryl | Buy | 135 000 | Employee Stock Option (Right to Buy) |
INSIDER POWER |
---|
83.93 |
Last 100 transactions |
Buy: 11 918 854 | Sell: 15 650 431 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.540 (-4.46% ) |
Volume | 0.0252 mill |
Avg. Vol. | 0.119 mill |
% of Avg. Vol | 21.10 % |
Signal 1: | |
Signal 2: |
114 Signals | Accuracy: 16.67% | Accuracy Buy: 12.28% | Accuracy Sell: 21.05%
Avg return buy: -1.68 % | Avg return sell: 0.93 %
$1 invested is now $0.37 or -62.89% since 21-04-22
Date | Signal | @ | Closed | % | May 16 - 09:42 | sell | $0.546 | N/A | Active |
---|---|---|---|---|
May 16 - 09:33 | buy | $0.570 | $0.560 @ May 16 - 09:41 | -1.82% |
May 13 - 13:00 | sell | $0.570 | $0.576 @ May 13 - 14:33 | 0.98% |
May 13 - 12:55 | buy | $0.571 | $0.570 @ May 13 - 12:59 | -0.21% |
May 13 - 12:48 | sell | $0.570 | $0.571 @ May 13 - 12:55 | 0.19% |
May 13 - 12:30 | buy | $0.570 | $0.570 @ May 13 - 12:47 | 0.00% |
May 12 - 12:44 | sell | $0.608 | $0.570 @ May 13 - 12:28 | -6.27% |
May 12 - 11:43 | buy | $0.627 | $0.608 @ May 12 - 12:43 | -3.05% |
May 12 - 11:39 | sell | $0.570 | $0.627 @ May 12 - 11:42 | 10.05% |
May 12 - 11:27 | buy | $0.556 | $0.570 @ May 12 - 11:38 | 2.48% |
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases. The company is also discovering liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.